Qualigen Therapeutics Inc 7R9

Overview

Qualigen Therapeutics, Inc. is a biotechnology firm established in 1996 and headquartered in Carlsbad, California. The company is committed to developing and commercializing innovative treatments for cancer and infectious diseases. Leveraging its expertise in biotechnology, Qualigen Therapeutics focuses on bringing novel therapeutic products to market, aiming to address some of the most challenging medical conditions with a focus on quality and speed. Their cutting-edge approach includes the development of drugs and therapeutic devices, heavily relying on both proprietary technologies and innovative research in the field.

Products and Services

• FastPack System - A patented, rapid onsite immunoassay testing system designed to improve diagnostic efficiency and accuracy. This product underscores the company's commitment to advancing diagnostic technologies alongside therapeutic products.
• QN-302 - Currently under development, QN-302 is targeted for the treatment of pancreatic ductal adenocarcinoma, a challenging and often deadly form of cancer. This exemplifies Qualigen's focus on targeted cancer therapies.
• QN-247 - An oligonucleotide-based drug candidate intended to treat a variety of cancers that express nucleolin, including both liquid and solid tumors. This approach reflects the company's strategy to tackle cancer through innovative molecular targeting.
• QN-165 - A drug candidate viewed as a potential broad-spectrum solution for infectious diseases, including COVID-19. Its development underscores the company's commitment to addressing urgent global health challenges.
• RAS-F - A small-molecule inhibitor targeting the RAS oncogene protein-protein interactions. By blocking RAS mutations and inhibiting tumor formation, RAS-F represents a novel approach to cancer treatment, reflecting Qualigen's focus on cutting-edge research in oncology.
• Selective Target Antigen Removal System - This therapeutic device is designed to remove circulating tumor cells, viruses, inflammation factors, and immune checkpoints from the body. It highlights Qualigen's innovative approach to treatment, aiming at directly eliminating the sources of disease.